12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Proellex telapristone regulatory update

Repros said FDA provided guidance for the company's clinical program for low-dose oral Proellex telapristone to treat uterine fibroids, which the agency put on a full clinical hold in 2009. Repros said FDA provided guidance on acceptable endpoints for the treatment of uterine fibroids and instructed the biotech to submit a request for lifting the hold at the same time it...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >